# US 2001/0027197 A1 · Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027197 A1
- Document ID: US20010027197A1
- Status: Published application
- Kind: A1
- Application number: 09/824,606
- Filed: 2001-04-02
- Published: 2001-10-04
- Earliest claimed: 1994-01-25
- Assignees: Warner-Lambert Company
- Inventors: Alexander James Bridges; William Alexander Denny; David Fry; Alan Kraker; Robert Frederick Meyer; Gordon William Rewcastle; Andrew Mark Thompson
- Web page: https://patentgrep.com/patent/US20010027197A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 473/34: attached in position 6, e.g. adenine
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are compounds and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: 1 where: one of A or E is nitrogen, with remaining atoms carbon; X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms). Other terms are described in the specification.

## Claims

### Claim 1

A method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II: 50
where:
one of A or E is nitrogen, with remaining atoms carbon;
X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);
n=0, 1, 2;
R1=H or lower alkyl (1-4 carbon atoms); if n=2, R1 can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom;
R2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo (fluoro, chloro, bromo, iodo), lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; —O—C(O)R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; —C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), sulfonamido, lower mono or dialkylsulfonamido (1-4 carbon atoms), mono or dicycloalkylsulfonamido (3-8 carbon atoms), mercapto, carboxy, carboxamido (—C(O)—NH2), lower mono or dialkylcarboxamido (1-4 carbon atoms), mono or dicycloalkylcarboxamido (3-8 carbon atoms), lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R2 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring; and
m=0-3,
Ar is selected from the group consisting of phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;
R3, R4, R5 and R6 are independently selected from the group consisting of H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms); carbonato (—OC(O)OR) where the R is lower alkyl of 1 to 4 carbon atoms or cycloalkyl of 3-8 carbon atoms;
ureido or thioureido or N- or O-linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);
lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino,N′-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, and lower O-alkylhydroxylamino (1-4 carbon atoms);
or optionally R3 and R4 or R4 and R6 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring;
any lower alkyl group substituent on any of the substituents in R3-R6 which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;
R8 is hydrogen, lower alkyl (1-4 carbon atoms), amino or mono or dialkyl (1-4 carbon atoms) amino;
with the proviso that R3 cannot be either OH or SH;
with the further proviso that at least one of the R3 and R4 or R4 and R6 substituents must be other than hydrogen, halogen, lower alkyl (1-4 carbon atoms) or lower alkoxy (1-4 carbon atoms);
optionally if any of the substituents R1, R2, R3, R4 or R6 have chiral centers, then all stereoisomers thereof both as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen and R3 or R4 H, with the other one lower alkoxy or halogen.

### Claim 3 (depends on 1)

The method of claim 1 wherein X=NH, n =0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen and R3 or R4 H, with the other one amino.

### Claim 4 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen and R3 or R4 H, with the other one lower mono or dialkylamino.

### Claim 5 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen and R3 and R4 lower alkyl.

### Claim 6 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen, and R3 or R4 amino, with the other one lower alkoxy.

### Claim 7 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen, and R3 or R4 lower mono or dialkylamino, with the other one lower alkoxy.

### Claim 8 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen and R3 lower mono or dialkylamino, with R4 hydroxy.

### Claim 9 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, B, D & E carbon, with A nitrogen, and R3 and R4 taken together are dioxymethylene, dioxyethylene, 2,3-fused piperazine, 2,3-fused morpholine or 2,3-fused thiomorpholine.

### Claim 10 (depends on 1)

The method of claim 1 having any one of the following ring structures: 51

### Claim 11 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 or R4 H, with the other one lower alkoxy.

### Claim 12 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 or R4 H, with the other one amino.

### Claim 13 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 or R4 H, with the other one lower mono or dialkylamino.

### Claim 14 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 or R4 H, with the other one hydrazino.

### Claim 15 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 or R4 H, with the other one lower alkyl.

### Claim 16 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 and R4 lower alkoxy.

### Claim 17 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R3 and R4 lower alkyl.

### Claim 18 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen, and R3 or R4 amino, with the other one lower alkoxy.

### Claim 19 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen, and R3 or R4 lower mono or dialkylamino, with the other one lower alkoxy.

### Claim 20 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R4 lower mono or dialkylamino, with R3 hydroxy.

### Claim 21 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen, and R2 and R4 taken together are dioxymethylene, dioxyethylene, 2,3-fused piperazine, 2,3-fused morpholine or 2,3-fused thiomorpholine.

### Claim 22 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen, and R3 or R4 lower mono or dialkylamino, with the other one lower alkoxy.

### Claim 23 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen and R4 lower mono or dialkylamino, with R3 hydroxy.

### Claim 24 (depends on 1)

The method of claim 1 wherein X=NH, n=0 or 1, in which case R1=H, the aromatic ring phenyl optionally substituted, A, B & D carbon, with E nitrogen, and R3 and R4 taken together are dioxymethylene, dioxyethylene, 2,3-fused piperazine, 2,3-fused morpholine or 2,3-fused thiomorpholine.

### Claim 25

A compound of Formula II 52
where:
one of A or E is nitrogen, with remaining atoms carbon;
X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);
n=0, 1, 2;
R1=H or lower alkyl (1-4 carbon atoms); if n=2, R1 can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom;
R2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo (fluoro, chloro, bromo, iodo), lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; —O—C(O)R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; —C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), sulfonamido, lower mono or dialkylsulfonamido (1-4 carbon atoms), mono or dicycloalkylsulfonamido (3-8 carbon atoms), mercapto, carboxy, carboxamido (—C(O)—NH2), lower mono or dialkylcarboxamido (1-4 carbon atoms), mono or dicycloalkylcarboxamido (3-8 carbon atoms), lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R2 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring; and
m=0-3,
Ar is selected from the group consisting of phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;
R3, R4, R5 and R6 are independently selected from the group consisting of H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms); carbonato (—OC(O)OR) where the R is lower alkyl of 1 to 4 carbon atoms or cycloalkyl of 3-8 carbon atoms;
ureido or thioureido or N- or O-linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);
lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino,N′-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, and lower O-alkylhydroxylamino (1-4 carbon atoms);
or optionally R3 and R4 or R4 and R6 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring;
any lower alkyl group substituent on any of the substituents in R3-R6 which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;
R8 is hydrogen, lower alkyl (1-4 carbon atoms), amino or mono or dialkyl (1-4 carbon atoms) amino;
with the proviso that R3 cannot be either OH or SH;
with the further proviso that at least one of the R3 and R4 or R4 and R6 substituents must be other than hydrogen, halogen, lower alkyl (1-4 carbon atoms) or lower alkoxy (1-4 carbon atoms);
with the further proviso that Formula II excludes ring structures where A or B is nitrogen when the A-E ring is a ring having 6 members;
optionally if any of the substituents R1, R2, R3, R4 or R6 have chiral centers, then all stereoisomers thereof both as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

### Claim 26

A pharmaceutical composition adapted for administration as an inhibitor of the epidermal growth factor receptor family of tyrosine kinases, comprising a therapeutically effective amount of a compound of Formula I or Formula II in admixture with a pharmaceutically acceptable excipient, diluent or carrier: 53
where:
one of A or E is nitrogen, with remaining atoms carbon;
X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);
n=0, 1, 2;
R1=H or lower alkyl (1-4 carbon atoms); if n=2, R1 can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom;
R2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo (fluoro, chloro, bromo, iodo), lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; —O—C(O)R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; —C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), sulfonamido, lower mono or dialkylsulfonamido (1-4 carbon atoms), mono or dicycloalkylsulfonamido (3-8 carbon atoms), mercapto, carboxy, carboxamido (—C(O)—NH2), lower mono or dialkylcarboxamido (1-4 carbon atoms), mono or dicycloalkylcarboxamido (3-8 carbon atoms), lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R2 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring; and
m=0-3,
Ar is selected from the group consisting of phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;
R3, R4, R5 and R6 are independently selected from the group consisting of H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms); carbonato (—OC(O)OR) where the R is lower alkyl of 1 to 4 carbon atoms or cycloalkyl of 3-8 carbon atoms;
ureido or thioureido or N- or O-linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);
lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino,N′-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, and lower O-alkylhydroxylamino (1-4 carbon atoms);
or optionally R3 and R4 or R4 and R6 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring;
any lower alkyl group substituent on any of the substituents in R3-R6 which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;
R8 is hydrogen, lower alkyl (1-4 carbon atoms), amino or mono or dialkyl (1-4 carbon atoms) amino;
with the proviso that R3 cannot be either OH or SH;
with the further proviso that at least one of the R3 and R4 or R4 and R6 substituents must be other than hydrogen, halogen, lower alkyl (1-4 carbon atoms) or lower alkoxy (1-4 carbon atoms);
with the further proviso that Formula II excludes ring structures where A or B is nitrogen when the A-E ring is a ring having 6 members;
optionally if any of the substituents R1, R2, R3, R4 or R6 have chiral centers, then all stereoisomers thereof both as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

### Claim 27

A method of treating cancer by treating, with an effective cancer inhibiting amount, a mammal, in need thereof, a compound of Formula I or Formula II: 54
where:
one of A or E is nitrogen, with remaining atoms carbon;
X=O, S, NH or NR7, such that R7=lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);
n=0, 1, 2;
R1=H or lower alkyl (1-4 carbon atoms); if n=2, R1 can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom;
R2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo (fluoro, chloro, bromo, iodo), lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; —O—C(O)R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; —C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), sulfonamido, lower mono or dialkylsulfonamido (1-4 carbon atoms), mono or dicycloalkylsulfonamido (3-8 carbon atoms), mercapto, carboxy, carboxamido (—C(O)—NH2), lower mono or dialkylcarboxamido (1-4 carbon atoms), mono or dicycloalkylcarboxamido (3-8 carbon atoms), lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R2 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring; and
m=0-3,
Ar is selected from the group consisting of phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;
R3, R4, R5 and R6 are independently selected from the group consisting of H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms); carbonato (—OC(O)OR) where the R is lower alkyl of 1 to 4 carbon atoms or cycloalkyl of 3-8 carbon atoms;
ureido or thioureido or N- or O-linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);
lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino,N′-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, and lower O-alkylhydroxylamino (1-4 carbon atoms);
or optionally R3 and R4 or R4 and R6 taken together on contiguous carbon atoms can form a carbocyclic ring of 5-7 members or a monounsaturated 1,3-dioxolanyl, 1,4-dioxanyl, 1,4-dioxepinyl, pyranyl, furanyl, pyrrolidyl, piperidinyl, thiolanyl, oxazolanyl, thiazolanyl, diazolanyl, piperazinyl, morpholino or thiomorpholino ring;
any lower alkyl group substituent on any of the substituents in R3-R6 which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;
R8 is hydrogen, lower alkyl (1-4 carbon atoms), amino or mono or dialkyl (1-4 carbon atoms) amino;
with the proviso that R3 cannot be either OH or SH;
with the further proviso that at least one of the R3 and R4 or R4 and R6 substituents must be other than hydrogen, halogen, lower alkyl (1-4 carbon atoms) or lower alkoxy (1-4 carbon atoms);
optionally if any of the substituents R1, R2, R3, R4 or R6 have chiral centers, then all stereoisomers thereof both as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

### Claim 28

A process for the preparation of 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine and pharmaceutically acceptable salts thereof which comprises:
Step (a) reaction of 5-amino-2-fluoropyridine with t-Boc anhydride to afford 5-[N-(tert-butoxycarbonyl)amino]-2-fluoropyridine;
Step (b) reaction of 5-[N-(tert-butoxycarbonyl)amino]-2-fluoropyridine sequentially with n-butyllithium and carbon dioxide to afford 5-[N-tert-butoxycarbonyl)amino]-2-fluoropyridine-4-carboxylic acid;
Step (c) reaction of 5-[N-tert-butoxycarbonyl)amino]-2-fluoropyridine-4-carboxylic acid with trifluoroacetic acid to afford 5-amino-2-fluoropyridine-4-carboxylic acid;
Step (d) reaction of 5-amino-2-fluoropyridine-4-carboxylic acid with formamide to afford 6-fluoro-3H-pyrido[3,4-d]pyrimidine-4-one;
Step (e) reaction of 6-fluoro-3H-pyrido[3,4-d]pyrimidine-4-one with phosphorus oxychloride to afford 4-chloro-6-fluoropyrido[3,4-d]pyrimidine;
Step (f) reaction of 4-chloro-6-fluoropyrido[3,4-d]pyrimidine with 3-bromoaniline to afford 4-(3-bromoanilino)-6-fluoropyrido[3,4-d]pyrimidine;
Step (g) reaction of 4-(3bromoanilino)-6-fluoropyrido[3,4-d]pyrimidine with methylamine to afford 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; and
Step (h) if desired converting 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine to a corresponding pharmaceutically acceptable salt by conventional means, and if so desired converting the corresponding pharmaceutically acceptable salt to 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine by conventional means.

### Claim 29

A compound which is 5-[N-(tert-butoxycarbonyl)amino]-2-fluoropyridine.

### Claim 30

A compound which is 5-[N-(tert-butoxycarbonyl)amino]-2-fluoropyridine-4-carboxylic acid.

### Claim 31

A compound which is 5-amino-2-fluoropyridine-4-carboxylic acid.

### Claim 32

A compound which is 6-fluoro-3H-pyrido [3,4-d]pyrimidine-4-one.

### Claim 33

A compound which is 4-chloro-6 fluoropyrido[3,4-d]pyrimidine.

### Claim 34

A compound which is 4-(3-bromoanilino)-6-fluoropyrido[3,4-d]pyrimidine.
